Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses: 2021-2024

Historic Other Operating Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $189.2 million.

  • Kiniksa Pharmaceuticals International's Other Operating Expenses rose 69.10% to $83.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.3 million, marking a year-over-year increase of 88.65%. This contributed to the annual value of $189.2 million for FY2024, which is 110.41% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Other Operating Expenses stood at $189.2 million for FY2024, which was up 110.41% from $89.9 million recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Other Operating Expenses peaked at $189.2 million during FY2024, and registered a low of $9.9 million during FY2021.
  • Moreover, its 3-year median value for Other Operating Expenses was $89.9 million (2023), whereas its average is $108.7 million.
  • Data for Kiniksa Pharmaceuticals International's Other Operating Expenses shows a peak YoY surged of 372.73% (in 2022) over the last 5 years.
  • Kiniksa Pharmaceuticals International's Other Operating Expenses (Yearly) stood at $9.9 million in 2021, then skyrocketed by 372.73% to $47.0 million in 2022, then soared by 91.48% to $89.9 million in 2023, then soared by 110.41% to $189.2 million in 2024.